BME:GRFBiotechs
Grifols Early Parkinson’s Signal Puts Plasma Know How To New Use
Grifols (BME:GRF) reported proof of concept data from its Chronos-PD program.
The company found molecular changes linked to Parkinson’s disease in blood plasma.
These changes were detected up to 12 years before clinical diagnosis.
Grifols, best known for its plasma derived therapies and diagnostic products, is extending that expertise into neurology with Chronos-PD. The early Parkinson’s signal in plasma connects directly to the company’s existing strengths in blood based testing, an area...